.jpg?format=webp&width=780)
Efficacy and safety data of heterologous prime-boost vaccination against SARS-CoV-2 remains limited. Heterologous ChAdOx1/mRNA-1273 vaccination provided higher immunogenicity than homologous ChAdOx1 vaccination and comparable immunogenicity with the homologous mRNA-1273 vaccination. The present study results support the safety and efficacy of heterologous prime-boost vaccination using the ChAdOx1 and mRNA-1273 COVID-19 vaccines.
Like
Save
Share